Last reviewed · How we verify
Jia Shen Tablet — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Jia Shen Tablet (Jia Shen Tablet) — Tasly Pharmaceutical Group Co., Ltd. The mechanism of action has not been publicly disclosed for this traditional Chinese medicine formulation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Jia Shen Tablet TARGET | Jia Shen Tablet | Tasly Pharmaceutical Group Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Jia Shen Tablet CI watch — RSS
- Jia Shen Tablet CI watch — Atom
- Jia Shen Tablet CI watch — JSON
- Jia Shen Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Jia Shen Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/jia-shen-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing